Vir Biotechnology Inc. VIR, -44.62% announced Thursday that a mid-stage clinical trial for a treatment of symptomatic influenza failed to achieve its main goals. The stock fell 40% in premarket. The Phase 2 Peninsula trial evaluated VIR-2482 to prevent symptomatic influenza A illnesses. It did not achieve its primary or secondary goal, according to a company statement. The statement stated that “in participants who received the maximum dose of VIR-2482 (1,000 mg), an approximate 16% reduction in protocol-defined influenza A illness was observed.” Participants who received the maximum dose experienced a 57% decrease in symptoms of influenza A. About 3,000 men, women and children aged 18-64 were involved in the trial. The results are disappointing but we need to do more analysis to understand them. We plan to present these findings at a major medical conference,” said Phil Pang M.D. Ph.D. Vir’s Interim Head and Executive Vice President of Research. The stock is down 9% year-to-date, while S&P500 SPX -0.56% is up 19%.